The Changing Face of Advanced Prostate Cancer 2023 Webcast (2024)

This is an ongoing course on advanced prostate cancer at the annual AUA since 2012, and the changes over the last decade have been nothing less than breathtaking! In the early years, it was all about metastatic castrate-resistant prostate cancer (CRPC) with multiple new therapeutic advances starting in 2010 followed by novel oral hormonal therapies and a focus on bone-targeted agents. Later, the course expanded to cover hormone-sensitive (HS) advanced disease due to the new data on chemotherapy and novel ADT extending survival in new M1 patients. In 2017, the topic of nonmetastatic CRPC (M0 CRPC) was added due to emerging data on use of novel oral hormonal agents in these men. In 2019, before COVID, the course expanded information on HS new M1 disease with emerging data that four therapeutic agents all improve survival for men with new metastatic prostate cancer. Some may have argued that the value of the course for urologists was a stretch back in 2012 because of the belief by some physicians that metastatic CRPC should be managed only by medical oncologists. However, over the last five years, the course is even more relevant to practicing urologists as most M0 CRPC and virtually all new M1 HS patients are initially managed by urologists and their advanced practice provider colleagues. In 2024, novel hormonal therapy is also newly FDA-approved for biochemical recurrence and will be covered. Using a case-based and multidisciplinary format, we will continue to push the boundaries of knowledge to urologists and their teams in covering this new toolbox of novel therapies. The course will have an academic urologist, a LUGPA (Large Urology Group Practice Association) private practice urologist and an academic medical oncologist.


This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Identify and treat a patient with newly diagnosed M1 prostate cancer with androgen deprivation therapy plus be able to offer novel ADT. Furthermore, recognize high-volume new M1 prostate cancer so as to be able to refer to a genitourinary medical oncologist for chemotherapy if necessary.
  2. Diagnose M0 CRPC, and be able to educate patients about using novel oral androgen receptor inhibitors added to traditional androgen deprivation therapy as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, understand the differences between these novel oral agents and educate patients about side effects and toxicities. Finally, understand the role or lack of role of prostate-specific membrane antigen PET in working up this disease state.
  3. Apply the latest phase III randomized controlled trial results for new therapies in M1 CRPC, and be able to educate their patients on treatment options and work on a multidisciplinary team caring for this disease state of far advanced prostate cancer.
  4. Identify that advanced prostate cancer is a complex group of disease states with a rapidly changing therapeutic landscape, and for providers and teams to embrace the multidisciplinary nature of care for our patients.
  5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents and novel androgen receptor-targeted agents emerging in 2024.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Morgans, AliciaBayerConsultant or AdvisorCurrent
Astra ZenecaConsultant or AdvisorCurrent
AstellasConsultant or AdvisorCurrent
SanofiConsultant or AdvisorCurrent
JanssenConsultant or AdvisorCurrent
DendreonConsultant or AdvisorCurrent
MerckConsultant or AdvisorCurrent
BMSConsultant or AdvisorCurrent
PfizerConsultant or AdvisorCurrent
MyovantConsultant or AdvisorCurrent
Advanced Accelerator ApplicationsConsultant or AdvisorCurrent
LantheusConsultant or AdvisorCurrent
MyriadConsultant or AdvisorCurrent
TelixConsultant or AdvisorCurrent
NovartisConsultant or AdvisorCurrent
Morris, David ScottAstellasConsultant or AdvisorCurrent
JanssenConsultant or AdvisorCurrent
BayerConsultant or AdvisorCurrent
MyriadConsultant or AdvisorCurrent
ClovisConsultant or Advisor12/01/2022
UroGen PharmaConsultant or AdvisorCurrent
AstraZenecaConsultant or AdvisorCurrent
MerckConsultant or AdvisorCurrent
InvitaeScientific Study or Trial12/31/2022
Decipher BioConsultant or AdvisorCurrent
TolmarConsultant or AdvisorCurrent
MyovantConsultant or AdvisorCurrent
ProgenicsConsultant or Advisor02/07/2023
PfizerMeeting Participant or LecturerCurrent
LantheusConsultant or AdvisorCurrent
Blue Earth DiagnosticsConsultant or AdvisorCurrent
Moul, Judd W.Sanofi-AventisMeeting Participant or LecturerCurrent
TheralogixConsultant or AdvisorCurrent
Janssen- J and JMeeting Participant or LecturerCurrent
PfizerScientific Study or TrialCurrent
AstellasMeeting Participant or LecturerCurrent
TolmarConsultant or AdvisorCurrent
Exosome DxMeeting Participant or LecturerCurrent
Blue Earth DiagnosticsMeeting Participant or LecturerCurrent
BayerConsultant or AdvisorCurrent
DendreonMeeting Participant or LecturerCurrent
MyovantScientific Study or TrialCurrent



PDF iconEducation Council Disclosures


PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2024
Expiration Date: May, 2025

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.